Navigation Links
Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
Date:12/7/2010

MOUNTAIN VIEW, Calif., Dec. 7, 2010 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration (FDA) in December to discuss the Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for AZ-004 (Staccato loxapine).  Alexza has submitted an Information Package to the FDA in preparation for the meeting, with the responses or proposals to the issues raised in the CRL.  AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

The Company anticipates the FDA meeting will be a comprehensive review of the issues identified by the FDA in the CRL, and Alexza's planned responses to those issues.  The Company's primary meeting goal is to clarify and fully understand the key issues, and to establish a plan to respond to those issues.  While the CRL follow-up meeting will be held in December, the Company does not expect the official FDA meeting minutes to be available until at least late January 2011.  The Company anticipates providing a further U.S. regulatory update on AZ-004 after receipt of the official FDA correspondence.

Alexza also announced today that it has met with the European Medicines Agency (EMA) and has received written confirmation that AZ-004 is eligible for submission of a Marketing Authorization Application (MAA) under the centralized registration procedure.  In addition, Alexza has been notified of the Rapporteur and Co-Rapporteur appointments for the AZ-004 review.  The Company believes that the comprehensive clinical development program for AZ-004 meets the requirements for the MAA filing.  Alexza expects to submit the MAA mid-year 2011.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/28/2014)... "Epithelial cell layers line all of the inner and ... for example in the lung, intestine, pancreas and in ... hair-like, microtubule-based structures – project from BBs and are ... through this exact positioning can cilia movements be coordinated ... from the lung or sound can be perceived from ...
(Date:10/28/2014)... hormonal therapy is known to substantially reduce breast ... about one-half of patients fail to take their ... Medical Center (CUMC) researchers has found that the ... type of hormone therapy), which are considerably less ... by 50 percent. , The study was published ...
(Date:10/28/2014)... study, researchers from Uppsala University demonstrate that elderly ... risk of developing Alzheimer,s disease than men without ... the scientific journal Alzheimer,s & Dementia . ... who were initially 50 year old, between the ... study show that self-reported sleep disturbances were linked ...
(Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
(Date:10/27/2014)... Do blood vessels that feed tumors differ from other blood ... led to the discovery of several genes that are more ... New research now reveals the normal function of one of ... for anticancer drug therapy. , A summary of the research ... 27. , The mystery of the gene, TEM5, began in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Blood vessel growth in the brain relies on a protein found in tumor blood vessels 2
... life hangs between life and death, suffering an extremely rare ... transplant, which will give him a new lease of life. ... will be donating a kidney each. , ,Mrs ... felt so helpless, especially as you're used to doing everything ...
... confirmed that the bird flu virus found in poultry in ... to humans as well //. ,As chief veterinarian ... laboratory that it was the highly pathogenic H5N1 strain of ... ,This is the first report of the H5N1 virus in ...
... Hospital's two pediatricians, Jo McCubbin and Peter Goss have ... months notice //. However a full time replacement ... ,This has led to concerns among obstetricians at ... obstetricians would not be able to deliver premature babies ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... Ramadoss Friday warned of "strong action" against "indiscipline" he ... of Medical Sciences// (AIIMS), saying a coterie had turned ... people have converted the AIIMS into a political hub ... return to New Delhi June 19," Ramadoss told reporters ...
... the Karolinska Institutet they have found ways to control the ... intestinal stem cell. The result of the study was published ... help in the development of new drugs for diseases such ... body, old cells are continually being replaced by new. If ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Mechanism of Stem Cell Regulation Identified 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... II Hybrid External Fixation System incorporating ... in hybrid fixation. It incorporates features ... is designed to offer speed of ... Hoffmann® snap-fit technology. , ,Using the ...
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
Medicine Products: